Medipharm Labs Corp T.LABS

Alternate Symbol(s): MEDIF

Healthcare Cannabis

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.

TSX:LABS - Post by User

Medipharm Labs Corp

<< Previous

Bullboard Posts

Next >>

Post by subaru1ion Sep 29, 2023 9:31am

72 Views

Post# 35661325

Yo....IF our Brazil partner is Eurofarma then we have a door

way into China and in my statement I am NOT including the collaboration between Pfizer and Eurofarma for COVID vaccines. Of particular note from below...."biosimilars", another name for generic drugs.

From May 2022....

Henlius and Eurofarma Entered into a License Agreement for Henlius' 3 Products in Latin America

2022-05-11

Shanghai, China, May 11th, 2022 - Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license and collaboration agreement with Eurofarma Laboratrios SA ("Eurofarma"), a leading Brazilian pharmaceutical company with considerable experience in introducing and marketing innovative medical products throughout Latin America, for the development, manufacturing and commercialization in 16 Latin American countries of Henlius' independently developed HANLIKANG (rituximab biosimilar), HANQUYOU (trastuzumab biosimilar, trade name in Europe: Zercepac®), and HANBEITAI (bevacizumab biosimilar). This collaboration is not only an endorsement of Henlius' product quality and operational strength, but also a continuation of the company's goal of advancing its worldwide footprint, building momentum for the company's evolution from biotechnology to biopharma.